Business Trends– category –
-
Interstellar Technologies Secures $47.24M from Japan SBIR, Establishes New Rocket Production Hub in Tohoku
Interstellar Technologies Inc. Japan Overview Japanese private space transport company Interstellar Technologies has secured $47.24 million from Japan's SBIR program and passed a key stage gate in JAXA's Space Strategic Fund program. Con... -
Resonac to Initiate High-Purity HF Gas Production at Tokuyama Plant by 2026, Strengthening Domestic Semiconductor Supply
Resonac (Official Press Release) / IBTimes JP Japan Overview Resonac announced it will begin producing high-purity hydrogen fluoride (HF) gas for semiconductors at its Tokuyama plant in Shunan City, Yamaguchi Prefecture, within 2026. Thi... -
Samsung and SK Hynix Announce Major HBM Capacity Expansions: Samsung Allocates Half to HBM4, Targeting 250K Wafers/Month by EOY 2026
Industry News / ChosunBiz South Korea Overview Samsung Electronics announced plans to increase its HBM production capacity by approximately 50% from 2025 levels, aiming for 250,000 semiconductor wafers per month by the end of 2026. The c... -
Ionis Forges $30M Ex-US Rare Disease Pact with Recordati, Accelerating Global ASO Reach
Fierce Biotech USA Overview Ionis Pharmaceuticals has secured a $30 million upfront payment from Recordati, granting the Italian firm exclusive ex-US development and commercialization rights for specific rare disease therapies. This stra... -
Elixirgen Therapeutics and Nippon Shinyaku Forge Alliance for Next-Gen DMD Therapy EXG-7001
GlobeNewswire Japan Overview Elixirgen Therapeutics and Nippon Shinyaku have signed an option agreement for the development and commercialization of EXG-7001, a promising therapeutic candidate for Duchenne Muscular Dystrophy (DMD). This ... -
Biotech CEOs Anticipate Funding Rebound by Late 2026, Pin Hopes on FDA for Streamlined Drug Development
Endpoints News USA Overview A recent Endpoints 100 survey reveals 62% of biotech CEOs anticipate a significant improvement in the funding environment by late 2026, driven by a recovering IPO market and increased M&A activity. These l... -
Antares and Novartis Forge $1.9B Deal to Tackle ‘Undruggable’ Cancer Targets with Small Molecules
Business Wire USA Overview Antares Therapeutics and Novartis have announced a strategic collaboration to discover, develop, and commercialize first-in-class small molecule therapies for previously 'undruggable' cancer targets. The agreem... -
Biogen Pivots Post-Apellis Acquisition: Halts Most R&D, Concentrates on Commercial Assets
Endpoints News USA Overview Biogen has confirmed it will suspend or terminate "most" of Apellis Pharmaceuticals' research programs and lay off some employees following its $5.6 billion acquisition. This strategic pivot is part of integra... -
BMS Reveals Promising Clinical Data for Next-Gen Blood Cancer Therapy Mezigdomide
BioPharma Dive USA Overview Bristol Myers Squibb (BMS) unveiled promising new clinical data for mezigdomide, its next-generation blood cancer therapy. This drug is one of two key protein degradation inducers BMS expects to succeed its mu... -
Novartis’ Acquired RNA Therapeutic del-brax Achieves Phase 1/2 Success for Muscle-Wasting Diseases
BioPharma Dive USA Overview Novartis' RNA therapeutic del-brax, acquired through its $12 billion purchase of Avidity Pharmaceuticals, successfully completed a Phase 1/2 clinical trial for muscle-wasting diseases, achieving its primary en...
